Publish date:

Monday's Health Winners & Losers

Merck is stronger.

Dow

component

Merck

(MRK) - Get Merck & Co., Inc. (MRK) Report

was trading higher after Citigroup upgraded the drugmaker to buy from hold. Merck was recently adding $1.88, or 4.4%, to $44.82.

Allergan

(AGN) - Get Allergan plc Report

was rising after a positive article in

Barron's

over the weekend said the Botox maker could benefit from the trend of retired baby-boomers drawing on their nest eggs. The stock was climbing $1.77, or 1.6%, to $114.12.

Novartis

(NVS) - Get Novartis AG Sponsored ADR Report

was falling after the Food and Drug Administration said it will need additional clinical trial data before granting U.S. approval for the sale of the company's diabetes drug Galvus. Shares of Novartis were lower by $1.46, or 2.5%, to $57.19.

Surgical-products producer

Stryker

(SYK) - Get Stryker Corporation Report

was downgraded as Wachovia lowered its rating on the company to market-perform from outperform. The stock was recently losing $1.67, or 2.6%, to $62.46.

Among health care winners Monday,

TheStreet Recommends

PDL BioPharma

(PDLI) - Get PDL BioPharma, Inc. Report

was recently up 2.4% to $19.96.

Abbott Laboratories

(ABT) - Get Abbott Laboratories Report

was tacking on 1.6% to $54.44.

Pfizer

(PFE) - Get Pfizer Inc. Report

was higher by 1% to $25.87.

Among decliners,

NeoPharm

(NEOL)

tumbled 11.4% to $2.04.

Elan

(ELN)

was off 3.3% to $13.41.

Genzyme

(GENZ)

eased by 1.7% to $63.21.